Back to top
more

DURECT (DRRX)

(Delayed Data from NSDQ)

$0.85 USD

0.85
11,088

0.00 (0.42%)

Updated Apr 24, 2024 11:40 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (147 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for DRRX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

DURECT Corporation [DRRX]

Reports for Purchase

Showing records 21 - 40 ( 140 total )

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 21

11/11/2021

Company Report

Pages: 7

First Ex-U.S. Patient Dosing Begins in Phase 2b AHFIRM Study of Larsucosterol for Severe AH; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 22

11/03/2021

Company Report

Pages: 7

3Q21 Recap; AHFIRM Continues Expansion Into New Clinical Sites; DUR-928 Officially Named Larsucosterol; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 23

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for DRRX

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 24

07/30/2021

Company Report

Pages: 6

2Q21 Recap: DUR-928 Phase 2b AHFIRM Clinical Sites to Expand Beyond U.S. in 2H21; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 25

05/05/2021

Company Report

Pages: 7

1Q21 Recap; DUR-928 Mechanism of Action As Epigenetic Regulator Underlies Effectiveness in AH; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 26

03/15/2021

Company Report

Pages: 8

4Q20 Recap: With POSIMIR Approved and Recent Raise, Focus Tightens on AH Opportunity; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 27

02/03/2021

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 28

02/02/2021

Company Report

Pages: 4

Surprise Approval

Provider: Roth Capital Partners, Inc.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 29

01/27/2021

Daily Note

Pages: 3

Potentially Pivotal Phase 2b AHFIRM Study in Severe AH Underway; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 30

12/16/2020

Daily Note

Pages: 3

FDA Fast Track Designation Points to Potential for Rapid Full Approval Timeline for DUR-928; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 31

12/08/2020

Daily Note

Pages: 4

DURECT Monetizes LACTEL Product Line For $15M, Consolidating Focus on DUR-928; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 32

11/23/2020

Company Report

Pages: 8

AHFIRM May Affirm DUR-928''s Potential as the New Treatment Paradigm for Severe AH

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 33

11/03/2020

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 34

11/03/2020

Company Report

Pages: 6

3Q20 Recap; Expecting a Busy 2021 for DUR-928 in Three Indications; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 35

11/02/2020

Company Report

Pages: 5

3Q20 Results

Provider: Roth Capital Partners, Inc.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 36

10/12/2020

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 37

10/11/2020

Company Report

Pages: 32

We are initiating coverage of DURECT Corporation with a Buy rating and 12-month Price Target of $7/share.

Provider: Roth Capital Partners, Inc.

Analyst: PIROS E

Price: 75.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 38

10/11/2020

Company Report

Pages: 32

We are initiatng coverage with a Buy rating and 12-month Price Target of $7/share

Provider: Roth Capital Partners, Inc.

Analyst: PIROS E

Price: 75.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 39

10/02/2020

Industry Report

Pages: 58

Final Program for Our Fourth Annual Virtual NASH Investor Conference

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 100.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 40

09/29/2020

Industry Report

Pages: 59

Program for Our Fourth Annual Virtual NASH Investor Conference, October 5

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 100.00

Research Provided by a Third Party